Functions of myc:max in the control of cell proliferation and tumorigenesis.
暂无分享,去创建一个
[1] S. Mai,et al. Genomic instability in MycER-activated Rat1A-MycER cells , 1996, Chromosome Research.
[2] R. Eisenman,et al. Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome. , 2004, Human molecular genetics.
[3] S. Cawley,et al. Unbiased Mapping of Transcription Factor Binding Sites along Human Chromosomes 21 and 22 Points to Widespread Regulation of Noncoding RNAs , 2004, Cell.
[4] J. Cleveland,et al. Mnt Loss Triggers Myc Transcription Targets, Proliferation, Apoptosis, and Transformation , 2004, Molecular and Cellular Biology.
[5] A. Wynshaw-Boris,et al. Evidence of Mnt-Myc Antagonism Revealed by Mnt Gene Deletion , 2004, Cell cycle.
[6] D. Felsher. Oncogenes as therapeutic targets. , 2004, Seminars in cancer biology.
[7] F. Conlon,et al. T‐box genes in early embryogenesis , 2004, Developmental dynamics : an official publication of the American Association of Anatomists.
[8] John L Cleveland,et al. Myc pathways provoking cell suicide and cancer , 2003, Oncogene.
[9] A. Ruddell,et al. B lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis. , 2003, The American journal of pathology.
[10] A. Kraft,et al. The PIM-2 Kinase Phosphorylates BAD on Serine 112 and Reverses BAD-induced Cell Death* , 2003, Journal of Biological Chemistry.
[11] T. Möröy,et al. Miz1 Is Required for Early Embryonic Development during Gastrulation , 2003, Molecular and Cellular Biology.
[12] J. Cleveland,et al. c-Myc Augments Gamma Irradiation-Induced Apoptosis by Suppressing Bcl-XL , 2003, Molecular and Cellular Biology.
[13] A. Wynshaw-Boris,et al. Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis , 2003, The EMBO journal.
[14] Elisa de Stanchina,et al. Tumor promotion by Mdm2 splice variants unable to bind p53. , 2003, Cancer research.
[15] Takashi Okamoto,et al. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis , 2003, Oncogene.
[16] D. Felsher,et al. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[17] G. Esparza-Gómez,et al. The spectrum of plasma cell neoplasia in oral pathology. , 2003, Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal.
[18] L. Chodosh,et al. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. , 2003, Genes & development.
[19] Ruedi Aebersold,et al. Quantitative proteomic analysis of chromatin-associated factors , 2003, Journal of the American Society for Mass Spectrometry.
[20] D. Livingston,et al. MYC recruits the TIP60 histone acetyltransferase complex to chromatin , 2003, EMBO reports.
[21] Peggy J. Farnham,et al. Analysis of Myc Bound Loci Identified by CpG Island Arrays Shows that Max Is Essential for Myc-Dependent Repression , 2003, Current Biology.
[22] B. Lüscher,et al. Stimulation of c‐MYC transcriptional activity and acetylation by recruitment of the cofactor CBP , 2003, EMBO reports.
[23] S. Kim,et al. Skp2 regulates Myc protein stability and activity. , 2003, Molecular cell.
[24] Andrea Cocito,et al. Genomic targets of the human c-Myc protein. , 2003, Genes & development.
[25] K. Nakayama,et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. , 2003, Molecular cell.
[26] B. Edgar,et al. Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. , 2003, Genes & development.
[27] M. Roussel,et al. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. , 2003, Molecular cell.
[28] M. Cole,et al. The Mad and Myc Basic Domains Are Functionally Equivalent* , 2003, The Journal of Biological Chemistry.
[29] T. Greiner,et al. Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis , 2003, The EMBO journal.
[30] R. Weinberg,et al. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. , 2003, Cancer cell.
[31] M. Eilers,et al. Transcriptional repression by Myc. , 2003, Trends in cell biology.
[32] S. Lowe,et al. Tumor suppression by Ink4a-Arf: progress and puzzles. , 2003, Current opinion in genetics & development.
[33] Stephen K. Burley,et al. X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors , 2003, Cell.
[34] M. Eilers,et al. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter , 2003, Oncogene.
[35] R. Eisenman,et al. Direct activation of RNA polymerase III transcription by c-Myc , 2003, Nature.
[36] Tapio Visakorpi,et al. Molecular genetics of prostate cancer , 2001, Urology.
[37] M. Moynahan,et al. The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans , 2002, Oncogene.
[38] P. Farnham,et al. Myc Recruits P-TEFb to Mediate the Final Step in the Transcriptional Activation of the cad Promoter* , 2002, The Journal of Biological Chemistry.
[39] Hans Clevers,et al. The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells , 2002, Cell.
[40] J. Massagué,et al. Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage , 2002, Nature.
[41] R. Eisenman,et al. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. , 2002, Genes & development.
[42] B. Edgar,et al. Why size matters: altering cell size. , 2002, Current opinion in genetics & development.
[43] Ruedi Aebersold,et al. Quantitative proteomic analysis of Myc oncoprotein function , 2002, The EMBO journal.
[44] John L Cleveland,et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. , 2002, Genes & development.
[45] Stella Pelengaris,et al. c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.
[46] Carla Grandori,et al. Modulation of T‐lymphocyte development, growth and cell size by the Myc antagonist and transcriptional repressor Mad1 , 2002, The EMBO journal.
[47] M. Eilers,et al. Negative regulation of the mammalian UV response by Myc through association with Miz-1. , 2002, Molecular cell.
[48] R. Eisenman,et al. Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[49] M. van Lohuizen,et al. The T-box Repressors TBX2 and TBX3Specifically Regulate the Tumor Suppressor Genep14 ARF via a Variant T-site in the Initiator* , 2002, The Journal of Biological Chemistry.
[50] M. Cole,et al. TRRAP-Dependent and TRRAP-Independent Transcriptional Activation by Myc Family Oncoproteins , 2002, Molecular and Cellular Biology.
[51] Kenneth Chu,et al. Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.
[52] G. Evan,et al. Myc-Is this the oncogene from Hell? , 2002, Cancer cell.
[53] P. Hurlin,et al. Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation , 2002, Oncogene.
[54] David M. Livingston,et al. A Complex with Chromatin Modifiers That Occupies E2F- and Myc-Responsive Genes in G0 Cells , 2002, Science.
[55] G. Evan,et al. Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression , 2002, Cell.
[56] Thierry Fest,et al. c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis , 2002, Oncogene.
[57] C. Albanese,et al. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. , 2002, Molecular cell.
[58] James M. Roberts,et al. MAD1 and p27KIP1 Cooperate To Promote Terminal Differentiation of Granulocytes and To Inhibit Myc Expression and Cyclin E-CDK2 Activity , 2002, Molecular and Cellular Biology.
[59] G. Wahl,et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. , 2002, Molecular cell.
[60] A. Menssen,et al. Characterization of the c-MYC-regulated transcriptome by SAGE: Identification and analysis of c-MYC target genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[61] John T. Powers,et al. ARF Differentially Modulates Apoptosis Induced by E2F1 and Myc , 2002, Molecular and Cellular Biology.
[62] M. MacDonald,et al. TBX-3, the Gene Mutated in Ulnar-Mammary Syndrome, Is a Negative Regulator of p19 ARF and Inhibits Senescence* , 2002, The Journal of Biological Chemistry.
[63] R. Kingston,et al. Cooperation between Complexes that Regulate Chromatin Structure and Transcription , 2002, Cell.
[64] M. Henriksson,et al. Repression of in vivo growth of Myc/Ras transformed tumor cells by Mad1 , 2002, Oncogene.
[65] Jeffrey M. Trimarchi,et al. Transcription: Sibling rivalry in the E2F family , 2002, Nature Reviews Molecular Cell Biology.
[66] Mark J. Murphy,et al. c-Myc regulates mammalian body size by controlling cell number but not cell size , 2001, Nature.
[67] D. Eick,et al. Myc/Max/Mad regulate the frequency but not the duration of productive cell cycles , 2001, EMBO reports.
[68] Bax Loss Impairs Myc-Induced Apoptosis and Circumvents the Selection of p53 Mutations during Myc-Mediated Lymphomagenesis , 2001, Molecular and Cellular Biology.
[69] F. Zindy,et al. Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. , 2001, Genes & development.
[70] P. Hurlin,et al. The interplay between Mad and Myc in proliferation and differentiation. , 2001, Trends in cell biology.
[71] B. Lüscher,et al. Function and regulation of the transcription factors of the Myc/Max/Mad network. , 2001, Gene.
[72] Charles J. Sherr,et al. The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.
[73] M. Eilers,et al. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. , 2001, Genes & development.
[74] P. Fernandez,et al. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. , 2001, Genes & development.
[75] M. Roussel,et al. Apoptosis Triggered by Myc-Induced Suppression of Bcl-XL or Bcl-2 Is Bypassed during Lymphomagenesis , 2001, Molecular and Cellular Biology.
[76] S. Kunjibettu,et al. The ATM-related domain of TRRAP is required for histone acetyltransferase recruitment and Myc-dependent oncogenesis. , 2001, Genes & development.
[77] M E Greenberg,et al. Myc requires distinct E2F activities to induce S phase and apoptosis. , 2001, Molecular cell.
[78] A. Hayday,et al. Defining the specific physiological requirements for c-Myc in T cell development , 2001, Nature Immunology.
[79] J. Massagué,et al. TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b , 2001, Nature Cell Biology.
[80] J. Massagué,et al. Repression of p15INK4b expression by Myc through association with Miz-1 , 2001, Nature Cell Biology.
[81] D. W. Kim,et al. Repression of transcription of the p27Kip1 cyclin-dependent kinase inhibitor gene by c-Myc , 2001, Oncogene.
[82] Nikita Popov,et al. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[83] B. Amati,et al. Function of the c-Myc oncoprotein in chromatin remodeling and transcription. , 2001, Biochimica et biophysica acta.
[84] A Ballabio,et al. WBSCR14, a gene mapping to the Williams--Beuren syndrome deleted region, is a new member of the Mlx transcription factor network. , 2001, Human molecular genetics.
[85] G. Evan,et al. Expression of Mad1 in T cells leads to reduced thymic cellularity and impaired mitogen-induced proliferation , 2001, Oncogene.
[86] R. Cardiff,et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations , 2001, Nature Medicine.
[87] R. Eisenman,et al. Targeted Deletion of the S-Phase-Specific Myc Antagonist Mad3 Sensitizes Neuronal and Lymphoid Cells to Radiation-Induced Apoptosis , 2001, Molecular and Cellular Biology.
[88] U. Weidle,et al. The transcriptional program of a human B cell line in response to Myc. , 2001, Nucleic acids research.
[89] F. Alt,et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. , 2001, Immunity.
[90] John N. Hutchinson,et al. Transgenic mouse models of human breast cancer , 2000, Oncogene.
[91] W. Hahn,et al. Genes involved in senescence and immortalization. , 2000, Current opinion in cell biology.
[92] E. Deitch,et al. G-protein receptor responses in trauma neutrophils. , 2000, The Journal of trauma.
[93] D. Ayer,et al. MondoA, a Novel Basic Helix-Loop-Helix–Leucine Zipper Transcriptional Activator That Constitutes a Positive Branch of a Max-Like Network , 2000, Molecular and Cellular Biology.
[94] W. Ansorge,et al. Induction of cyclin E–cdk2 kinase activity, E2F‐dependent transcription and cell growth by Myc are genetically separable events , 2000, The EMBO journal.
[95] Marc J. van de Vijver,et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19ARF) and is amplified in a subset of human breast cancers , 2000, Nature Genetics.
[96] A. Iavarone,et al. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins , 2000, Nature.
[97] M. Cole,et al. Complementation of Myc-dependent cell proliferation by cDNA expression library screening , 2000, Oncogene.
[98] Y Taya,et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.
[99] S. R. Hann,et al. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[100] T. Fotsis,et al. The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A. , 2000, Cancer research.
[101] M. Roussel,et al. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. , 2000, Genes & development.
[102] G. Daley,et al. A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts , 2000, Oncogene.
[103] A. Reymond,et al. Mlx, a new Max-like bHLHZip family member: the center stage of a novel transcription factors regulatory pathway? , 2000, Oncogene.
[104] R. Eisenman,et al. Analysis of Myc/Max/Mad network members in adipogenesis: Inhibition of the proliferative burst and differentiation by ectopically expressed Mad1 , 2000, Journal of cellular physiology.
[105] F. Alt,et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. , 2000, Genes & development.
[106] P. Neiman,et al. Angiogenesis is an early event in the generation of myc-induced lymphomas , 2000, Oncogene.
[107] N. Mailand,et al. Involvement of Myc Activity in a G1/S-Promoting Mechanism Parallel to the pRb/E2F Pathway , 2000, Molecular and Cellular Biology.
[108] O. Volpert,et al. An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[109] E. Lander,et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[110] J F Barrett,et al. Identification of CDK4 as a target of c-MYC. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[111] T. Littlewood,et al. Action of Myc in vivo - proliferation and apoptosis. , 2000, Current opinion in genetics & development.
[112] M. Cole,et al. An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. , 2000, Molecular cell.
[113] Ken Chen,et al. Gene-target recognition among members of the Myc superfamily and implications for oncogenesis , 2000, Nature Genetics.
[114] B. Amati,et al. Myc induces the nucleolin and BN51 genes: possible implications in ribosome biogenesis. , 2000, Nucleic acids research.
[115] M. Cole,et al. The Essential Cofactor TRRAP Recruits the Histone Acetyltransferase hGCN5 to c-Myc , 2000, Molecular and Cellular Biology.
[116] E. Mekada,et al. Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras , 2000, Oncogene.
[117] R. DePinho,et al. Essential role for Max in early embryonic growth and development. , 2000, Genes & development.
[118] R. Eisenman,et al. The Myc/Max/Mad network and the transcriptional control of cell behavior. , 2000, Annual review of cell and developmental biology.
[119] Gustavo Droguett,et al. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation , 2000, Nature Cell Biology.
[120] D. Ayer,et al. Mlx, a Novel Max-like BHLHZip Protein That Interacts with the Max Network of Transcription Factors* , 1999, The Journal of Biological Chemistry.
[121] N. Jenkins,et al. Mga, a dual‐specificity transcription factor that interacts with Max and contains a T‐domain DNA‐binding motif , 1999, The EMBO journal.
[122] R. Eisenman,et al. Dwarfism and dysregulated proliferation in mice overexpressing the MYC antagonist MAD1. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[123] R. Eisenman,et al. c-Myc enhances protein synthesis and cell size during B lymphocyte development. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[124] U. Weidle,et al. Control of cell growth by c-Myc in the absence of cell division , 1999, Current Biology.
[125] S. Lowe,et al. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.
[126] M. Roussel,et al. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.
[127] W. Ansorge,et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27 , 1999, The EMBO journal.
[128] A. Sewing,et al. Cyclins D1 and D2 mediate Myc‐induced proliferation via sequestration of p27Kip1 and p21Cip1 , 1999, The EMBO journal.
[129] D. Prober,et al. Drosophila myc Regulates Cellular Growth during Development , 1999, Cell.
[130] J. Tonn,et al. Analysis of the max‐binding protein MNT in human medulloblastomas , 1999, International journal of cancer.
[131] L. Kedes,et al. Twist is a potential oncogene that inhibits apoptosis. , 1999, Genes & development.
[132] M. Schwab,et al. Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells. , 1999, European journal of biochemistry.
[133] D. Felsher,et al. Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.
[134] A. Kraft,et al. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway , 1999, Oncogene.
[135] John M. Sedivy,et al. c-Myc Regulates Cyclin D-Cdk4 and -Cdk6 Activity but Affects Cell Cycle Progression at Multiple Independent Points , 1999, Molecular and Cellular Biology.
[136] James M. Roberts,et al. CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.
[137] M. Cole,et al. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation , 1999, Oncogene.
[138] G. Evan,et al. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. , 1999, Molecular cell.
[139] S. G. Cheng,et al. c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function , 1999, Nature Genetics.
[140] M. Roussel,et al. Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[141] L. Chin,et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation , 1999, Oncogene.
[142] J. Nevins,et al. Ras enhances Myc protein stability. , 1999, Molecular cell.
[143] R. Dalla‐Favera,et al. Direct activation of TERT transcription by c-MYC , 1999, Nature Genetics.
[144] K Kornfeld,et al. Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. , 1999, Genes & development.
[145] M. Cole,et al. The Novel ATM-Related Protein TRRAP Is an Essential Cofactor for the c-Myc and E2F Oncoproteins , 1998, Cell.
[146] J L Cleveland,et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.
[147] R. DePinho,et al. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth , 1998, Nature.
[148] D. Ledbetter,et al. The human ROX gene: genomic structure and mutation analysis in human breast tumors. , 1998, Genomics.
[149] A. M. Morrison,et al. Identification of BSAP (Pax‐5) target genes in early B‐cell development by loss‐ and gain‐of‐function experiments , 1998, The EMBO journal.
[150] H. Konishi,et al. Molecular Analysis of a Myc Antagonist, ROX/Mnt, at 17p13.3 in Human Lung Cancers , 1998, Japanese journal of cancer research : Gann.
[151] E. Kremmer,et al. Identification and Characterization of Specific DNA-binding Complexes Containing Members of the Myc/Max/Mad Network of Transcriptional Regulators* , 1998, The Journal of Biological Chemistry.
[152] R. Eisenman,et al. Sequential expression of the MAD family of transcriptional repressors during differentiation and development , 1998, Oncogene.
[153] R. Eisenman,et al. Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation , 1998, The EMBO journal.
[154] C. Y. Wang,et al. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. , 1997, Science.
[155] W. Ansorge,et al. Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes , 1997, Oncogene.
[156] L. Hennighausen,et al. Cre-mediated gene deletion in the mammary gland. , 1997, Nucleic acids research.
[157] J. Sedivy,et al. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[158] R. Bernards,et al. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity , 1997, Oncogene.
[159] J. Nevins,et al. Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals , 1997, Molecular and cellular biology.
[160] R A Jungmann,et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[161] E. Kremmer,et al. Cell growth inhibition by the Mad/Max complex through recruitment of histone deacetylase activity , 1997, Current Biology.
[162] Joseph R. Nevins,et al. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F , 1997, Nature.
[163] Andreas Sewing,et al. Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27Kip1 binding to newly formed complexes , 1997, Oncogene.
[164] D. Ledbetter,et al. Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non‐canonical E box and acts as a transcriptional repressor , 1997, The EMBO journal.
[165] Wen‐Ming Yang,et al. Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression , 1997, Cell.
[166] Stuart L Schreiber,et al. Histone Deacetylase Activity Is Required for Full Transcriptional Repression by mSin3A , 1997, Cell.
[167] S. Lowe,et al. Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.
[168] R. Eisenman,et al. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. , 1997, Genes & development.
[169] R. Eisenman,et al. Mnt: a novel Max-interacting protein and Myc antagonist. , 1997, Current topics in microbiology and immunology.
[170] M. Linial,et al. Viral Myc Oncoproteins in Infected Fibroblasts Down-modulate Thrombospondin-1, a Possible Tumor Suppressor Gene* , 1996, The Journal of Biological Chemistry.
[171] An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. , 1996, Molecular and cellular biology.
[172] D. Beach,et al. Cdc25 cell-cycle phosphatase as a target of c-myc , 1996, Nature.
[173] M. Roussel,et al. Inhibition of cell proliferation by the Mad1 transcriptional repressor , 1996, Molecular and cellular biology.
[174] W. Ansorge,et al. Activation of cyclin‐dependent kinases by Myc mediates induction of cyclin A, but not apoptosis. , 1996, The EMBO journal.
[175] R. DePinho,et al. Expression and activity of L-Myc in normal mouse development , 1996, Molecular and cellular biology.
[176] D. Hanahan,et al. Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. , 1995, Oncogene.
[177] M. Pagano,et al. Identification of a Myc‐dependent step during the formation of active G1 cyclin‐cdk complexes. , 1995, The EMBO journal.
[178] C. Seelos,et al. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins. , 1995, Oncogene.
[179] G. Evan,et al. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. , 1995, Nucleic acids research.
[180] R. Eisenman,et al. Mad-max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3 , 1995, Cell.
[181] L. Chin,et al. An amino-terminal domain of Mxi1 mediates anti-myc oncogenic activity and interacts with a homolog of the Yeast Transcriptional Repressor SIN3 , 1995, Cell.
[182] R. Eisenman,et al. Overexpressed max is not oncogenic and attenuates myc-induced lymphoproliferation and lymphomagenesis in transgenic mice. , 1995, Oncogene.
[183] N. Hay,et al. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. , 1994, Genes & development.
[184] H. Hermeking,et al. Mediation of c-Myc-induced apoptosis by p53. , 1994, Science.
[185] G. Prendergast,et al. c‐Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. , 1994, The EMBO journal.
[186] R. DePinho,et al. Suppression of Myc, but not E1a, transformation activity by Max-associated proteins, Mad and Mxi1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[187] G. Evan,et al. The c‐Myc protein induces cell cycle progression and apoptosis through dimerization with Max. , 1993, The EMBO journal.
[188] G. Casey,et al. Functional evidence for a breast cancer growth suppressor gene on chromosome 17. , 1993, Human molecular genetics.
[189] G. Merlo,et al. A Locus on Chromosome 17P13.3, Associated with a High S‐Phase Index Is Distinct from the p53 Gene in Breast Cancer a , 1993, Annals of the New York Academy of Sciences.
[190] R. Eisenman,et al. A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. , 1993, Genes & development.
[191] J. Rossant,et al. Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus. , 1993, Development.
[192] D. Gillespie,et al. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity. , 1993, Oncogene.
[193] Stephen K. Burley,et al. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain , 1993, Nature.
[194] A. Bradley,et al. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. , 1993, Genes & development.
[195] H. Kondoh,et al. Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse. , 1993, Development.
[196] R. Brent,et al. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites , 1993, Cell.
[197] Bruno Amati,et al. Oncogenic activity of the c-Myc protein requires dimerization with Max , 1993, Cell.
[198] R. Eisenman,et al. Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity , 1993, Cell.
[199] N. Hay,et al. Sequence-specific transcriptional activation by Myc and repression by Max , 1993, Molecular and cellular biology.
[200] V. Stewart,et al. Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. , 1992, Genes & development.
[201] A. Perkins,et al. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. , 1992, Genes & development.
[202] G. Evan,et al. Cooperative interaction between c-myc and bcl-2 proto-oncogenes , 1992, Nature.
[203] R. Eisenman,et al. Myc and Max proteins possess distinct transcriptional activities , 1992, Nature.
[204] G. Evan,et al. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max , 1992, Nature.
[205] K. Alitalo,et al. Amplification and rearrangement of L-myc in human small-cell lung cancer. , 1992, Mutation research.
[206] K. Alitalo,et al. Alternative Forms of Max as Enhancers or Suppressors of Myc-Ras Cotransformation , 1992, Science.
[207] Gerard I. Evan,et al. Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.
[208] M. Cole,et al. Casein kinase II inhibits the DNA-binding activity of Max homodimers but not Myc/Max heterodimers. , 1992, Genes & development.
[209] R. Eisenman,et al. Myc and Max associate in vivo. , 1992, Genes & development.
[210] A. Patel,et al. myc function and regulation. , 1992, Annual review of biochemistry.
[211] C. Dang,et al. Max: functional domains and interaction with c-Myc. , 1992, Genes & development.
[212] J. Cleveland,et al. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.
[213] A. Berns. Tumorigenesis in transgenic mice: Identification and characterization of synergizing oncogenes , 1991, Journal of cellular biochemistry.
[214] G. Prendergast,et al. Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation , 1991, Cell.
[215] H. Kondoh,et al. Embryonic lethality resulting from disruption of both N-myc alleles in mouse zygotes. , 1991, The New biologist.
[216] J. Bishop,et al. The MYC protein activates transcription of the alpha‐prothymosin gene. , 1991, The EMBO journal.
[217] K. Alitalo,et al. Expression of the myc proto-oncogenes in developing human fetal brain. , 1990, Oncogene.
[218] R. Eisenman,et al. New light on Myc and Myb. Part II. Myb. , 1990, Genes & development.
[219] H. Weintraub,et al. Sequence-specific DNA binding by the c-Myc protein. , 1990, Science.
[220] A. Strasser,et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.
[221] J. Barrett,et al. An amino-terminal c-myc domain required for neoplastic transformation activates transcription , 1990, Molecular and cellular biology.
[222] E. Prochownik,et al. The leucine zipper of c-Myc is required for full inhibition of erythroleukemia differentiation , 1990, Molecular and cellular biology.
[223] C. Dang,et al. Definition of the activities and properties of c-myc required to inhibit cell differentiation. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[224] D. Gillespie,et al. The leucine zipper domain of avian cMyc is required for transformation and autoregulation. , 1990, Oncogene.
[225] R. Stein,et al. Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[226] Didier Picard,et al. Chimaeras of Myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells , 1989, Nature.
[227] J. Bishop,et al. Contrasting patterns of myc and N-myc expression during gastrulation of the mouse embryo. , 1989, Genes & development.
[228] David Baltimore,et al. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins , 1989, Cell.
[229] C. Dang,et al. Involvement of the 'leucine zipper' region in the oligomerization and transforming activity of human c-myc protein , 1989, Nature.
[230] F. Alt,et al. N-myc proto-oncogene expression during organogenesis in the developing mouse as revealed by in situ hybridization , 1988, The Journal of cell biology.
[231] S. Freytag. Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1 , 1988, Molecular and cellular biology.
[232] M. Goldfarb,et al. Growth factor-deprived BALB/c 3T3 murine fibroblasts can enter the S phase after induction of c-myc gene expression , 1987, Molecular and cellular biology.
[233] P. Leder,et al. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo , 1987, Cell.
[234] K. Maruyama,et al. myc and E1A oncogenes alter the responses of PC12 cells to nerve growth factor and block differentiation. , 1987, Oncogene.
[235] V. Sorrentino,et al. Potentiation of growth factor activity by exogenous c-myc expression. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[236] E. Prochownik,et al. Deregulated expression of c-myc by murine erythroleukaemia cells prevents differentiation , 1986, Nature.
[237] E. Dmitrovsky,et al. Expression of a transfected human c-myconcogene inhibits differentiation of a mouse erythroleukaemia cell line , 1986, Nature.
[238] A. Kimchi,et al. Autocrine β-related interferon controls c-myc suppression and growth arrest during hematopoietic cell differentiation , 1986, Cell.
[239] M. Cole,et al. Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment , 1986, Nature.
[240] M. Cole. The myc oncogene: its role in transformation and differentiation. , 1986, Annual review of genetics.
[241] F. Alt,et al. Differential expression of myc family genes during murine development , 1986, Nature.
[242] R. Palmiter,et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.
[243] J. Cleveland,et al. Abrogation of IL-3 and IL-2 dependence by recombinant murine retroviruses expressing v-myc oncogenes , 1985, Nature.
[244] E. Knight,et al. Selective reduction of c-myc mRNA in Daudi cells by human beta interferon. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[245] Robert A. Weinberg,et al. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes , 1983, Nature.
[246] J. Bishop,et al. DNA and RNA from Uninfected Vertebrate Cells Contain Nucleotide Sequences Related to the Putative Transforming Gene of Avian Myelocytomatosis Virus , 1979, Journal of virology.
[247] J. Bishop,et al. Identification of nucleotide sequences which may encode the oncogenic capacity of avian retrovirus MC29 , 1978, Journal of virology.
[248] U. Heine,et al. Strain MC29 avian leukosis virus. Myelocytoma, endothelioma, and renal growths: pathomorphological and ultrastructural aspects. , 1967, Journal of the National Cancer Institute.